| ABSTRACT Objective：The paper is to observe and explore clinical efficacy of arsenic trioxide embolization combined with
hepatic artery interventional therapy in treatment of metastatic liver cancer. Methods：33 metastatic liver cancer patients from 2010 to
2012 of Liaoning Province Tumor Hospital were chosen as study objects, of which hepatic artery angiography and indirect portal vein
angiography were performed, according to results of hepatic artery angiography or portal vein angiography, treatment of arsenic trioxide
embolism chemotherapy of hepatic artery and hepatic arterial infusion chemotherapy were taken, 3-4 weeks for one therapeutic cycle,
after total completion of 4 treatment cycles, clinical efficiency was noted and compared between 2 kinds of Interventional therapies, and
survival rate for half a year, 1 years, 2 years was followed after treatment.Results： ①After interventional treatment, clinical symptoms of
patients were all improved, KPS score was significantly higher than that of pre-treatment (P<0.05), and total clinical efficiency rate was
81.82%. ② Patients' survival rates for 6 months, 1 year, 2 year were 90.91%, 66.67%, 33.33% respectively, hepatic artery embolism
chemotherapy patients with higher long-term survival rate than patients conducted hepatic arterial infusion chemotherapy.
Conclusion：Arsenic trioxide can inhibit cancer cell from multiple perspectives, whose clinical application is effective. For metastatic liver cancer
patients who were not suitable for operation, proper hepatic artery interventional therapy should be selected based on hepatic artery blood
supply and other characteristics, which will get satisfactory curative effect. |
